XML 43 R20.htm IDEA: XBRL DOCUMENT v3.19.3
Note 12 - Subsequent Event
6 Months Ended
Sep. 30, 2019
Notes to Financial Statements  
Subsequent Events [Text Block]
Note
12
.
Subsequent Event
 
In
October 
2019,
we announced that our Board of Directors declared a quarterly cash dividend of
$0.16
per share of common stock, payable on
December 
16,
2019,
to shareholders of record at the close of business on
November 29, 2019.
 
On
October 31, 2019,
we completed a business combination (the "GPT Acquisition") whereby we acquired the common stock of Gyros Protein Technologies Holding AB ("GPT"), a company whose business provides Immunoassay and Peptide Synthesis solutions that accelerate the discovery, development and manufacturing of biotherapeutics.  The acquisition price for GPT consisted of cash consideration of
$180,000,
subject to purchase price adjustments. The acquisition deepens our commitment to biopharmaceutical quality control and is the core of our new division, or segment, Biopharmaceutical Development.  As the acquisition was recently consummated, we have
not
completed our purchase accounting and are unable to provide the required additional footnote disclosures.